RT Journal Article
SR Electronic
T1 Proton Therapy for Primary Renal Cell Carcinoma: The First Nationwide Retrospective Study in Japan
JF In Vivo
JO In Vivo
FD International Institute of Anticancer Research
SP 2883
OP 2889
DO 10.21873/invivo.12116
VO 34
IS 5
A1 NOBUYOSHI FUKUMITSU
A1 HITOSHI ISHIKAWA
A1 TAKESHI ARIMURA
A1 HITOSHI WADA
A1 TOMOAKI OKIMOTO
A1 YOSHITAKA SATO
A1 HIROMITSU IWATA
A1 SHOSEI SHIMIZU
A1 HIDEYUKI SAKURAI
YR 2020
UL http://iv.iiarjournals.org/content/34/5/2883.abstract
AB Background/Aim: This multi-institutional study aimed to investigate the efficacy and feasibility of proton beam therapy (PBT) for renal cell carcinoma (RCC) in Japan. Patients and Methods: The survival, local control, and toxicities in 22 RCC patients treated between 2001 and 2016 at 6 Japanese PBT institutes were analyzed. Results: The 22 patients comprised 20 men and had a median age of 67 (range=42-88) years. The total irradiation dose was 60-79.6 Gy (relative biological effectiveness). Over a median follow-up of 37 months, the 3-year overall and disease-specific survival rates were 95% and 100%, respectively, and no recurrence occurred. No patient experienced grade 3 or higher adverse events. The serum blood urea nitrogen (p=0.25) and creatinine levels (p=0.95) were not significantly affected, although the mean estimated glomerular filtration rate was reduced by 7.1±11.2 ml/min/1.73 m2. Conclusion: Despite the small number of patients, high-dose PBT can control RCC while maintaining their renal function with high probability, and could be and alternative curative therapy especially for inoperable patients.